Jessa Elaine Miller

Dr. Jessa Elaine Miller

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2013 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
CAChristopher J. Alteri
Christopher J. Alteri
SHStephanie D. Himpsl
Stephanie D. Himpsl
SPShannon R. Pickens
Shannon R. Pickens
JLJonathon R. Lindner
Jonathon R. Lindner
JZJonathan S. Zora
Jonathan S. Zora
HMHarry Mobley
Harry Mobley
The Type VI Secretion System (T6SS) functions in bacteria as a contractile nanomachine that punctures and delivers lethal effectors to a target cell. Virtually nothing is known about the lifestyle or physiology that dictates when bacteria normally produce their T6SS, which prevents a clear understanding of how bacteria benefit from its action in their natural habitat. Proteus mirabilis undergoes a characteristic developmental process to coordinate a multicellular swarming behavior and will discriminate itself from another Proteus isolate during swarming, resulting in a visible boundary termed a Dienes line. Using transposon mutagenesis, we discovered that this recognition phenomenon requires the lethal action of the T6SS. All mutants identified in the genetic screen had insertions within a single 33.5-kb region that encodes a T6SS and cognate Hcp-VrgG-linked effectors. The identified T6SS and primary effector operons were characterized by killing assays, by construction of additional mutants, by complementation, and by examining the activity of the type VI secretion system in real-time using live-cell microscopy on opposing swarms. We show that lethal T6SS-dependent activity occurs when a dominant strain infiltrates deeply beyond the boundary of the two swarms. Using this multicellular model, we found that social recognition in bacteria, underlying killing, and immunity to killing all require cell-cell contact, can be assigned to specific genes, and are dependent on the T6SS. The ability to survive a lethal T6SS attack equates to “recognition”. In contrast to the current model of T6SS being an offensive or defensive weapon our findings support a preemptive mechanism by which an entire population indiscriminately uses the T6SS for contact-dependent delivery of effectors during its cooperative mode of growth. Bacterial Type VI Secretion Systems (T6SS) function as contractile nanomachines to puncture target cells and deliver lethal effectors. Little is known about the lifestyle or physiology dictating when bacteria normally express their T6SS. Proteus mirabilis undergoes a characteristic developmental process to coordinate multicellular swarming behavior and discriminates itself from other Proteus isolates during swarming, by a visible boundary termed a Dienes line. We report this phenomenon, first noted in 1946, requires the lethal action of the T6SS, T6SS-dependent effectors, and immunity proteins. T6SS-mediated lethality is unique to morphologically distinct swarmer cells, and when it occurs requires direct contact. Using this multicellular system, we report that the pre-formed T6SS strikes neighboring cells upon cell-cell contact. Our findings support a preemptive mechanism by which an entire population indiscriminately uses the T6SS during a cooperative behavior and that social recognition in bacteria is immunity to lethal T6SS attack.

20 November 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
CAChristopher J Alteri
Christopher J Alteri
SHStephanie D Himpsl
Stephanie D Himpsl
KZKevin Zhu
Kevin Zhu
HHHaley L Hershey
Haley L Hershey
NMNinette Musili
Ninette Musili
HMHarry Mobley
Harry Mobley
Type VI secretion systems (T6SS) function to deliver lethal payloads into target cells. Many studies have shown that protection against a single, lethal T6SS effector protein requires a cognate antidote immunity protein, both of which are often encoded together in a two-gene operon. The T6SS and an effector-immunity pair is sufficient for both killing and immunity. HereIn this paper we describe a T6SS effector operon that differs from conventional effector-immunity pairs in that eight genes are necessary for lethal effector function, yet can be countered by a single immunity protein. In this study, we investigated the role that the PefE T6SS immunity protein plays in recognition between two strains harboring nearly identical effector operons. Interestingly, despite containing seven of eight identical effector proteins, the less conserved immunity proteins only provided protection against their native effectors, suggesting that specificity and recognition could be dependent on variation within an immunity protein and one effector gene product. The variable effector gene product, PefD, is encoded upstream from pefE, and displays toxic activity that can be countered by PefE independent of T6SS-activity. Interestingly, while the entire pef operon was necessary to exert toxic activity via the T6SS in P. mirabilis, production of PefD and PefE alone was unable to exert this effector activity. Chimeric PefE proteins constructed from two P. mirabilis strains were used to localize immunity function to three amino acids. A promiscuous immunity protein was created using site-directed mutagenesis to change these residues from one variant to another. These findings support the notion that subtle differences between conserved effectors are sufficient for T6SS-mediated kin discrimination and that PefD requires additional factors to function as a T6SS-dependent effector. Bacterial type VI secretion systems (T6SS) function as contractile nanomachines to puncture target cells and deliver lethal effectors. Little is known about the lifestyle or physiology dictating when bacteria normally express their T6SS. Previously, we have reported that discrimination of self during the multicellular swarming behavior of Proteus mirabilis requires the lethal action of the T6SS, T6SS-dependent effectors, and immunity proteins. Bacteria that share common immunity proteins are protected against T6SS killing and recognize each other as self. Here we introduce a new group of T6SS immunity effectors that require eight genes for killing and a single immunity gene that differs from the classical effector-immunity pairs. Variation within an effector operon drives specificity and recognition between strains. We propose that subtle sequence variation in the effector operons contribute to self and non-self recognition in these bacteria.

1 May 2018 in Thyroid®
Verified
Journal Article
Closed access
JMJessa Elaine Miller
Jessa Elaine Miller
NANeal C. Al-Attar
Neal C. Al-Attar
OBOwen H. Brown
Owen H. Brown
GSGabrielle G. Shaughness
Gabrielle G. Shaughness
NRNatalja P. Rosculet
Natalja P. Rosculet
DHDavid T. Hughes
David T. Hughes
Background: After initial surgical treatment of differentiated thyroid cancer (DTC) residual lymph node metastases are often found at the time of radioactive iodine (131-I) therapy. Recurrence of DTC is due to persistent disease not removed at initial surgery and that did not respond to 131-I treatment. This study aims to determine locations of, and reasons for, residual nodal metastases detected by 131-I scans with SPECT/CT obtained prior to radioiodine therapy following surgical treatment of DTC. Methods: This is a retrospective study of 352 patients with intermediate and high-risk DTC treated with 131-I therapy at the University of Michigan from 2007–2014. All patients underwent total thyroidectomy with or without lymph node dissection followed by radioiodine therapy. Pre-ablation diagnostic 131-I scans with SPECT/CT were used postoperatively to localize nodal metastases, which were then compared with the cervical lymph node basins dissected at the time of surgery to determine the reason for residual nodal metastases: incomplete nodal dissection versus preoperative unrecognized nodal metastases. Results: 146/352 (41.5%) patients had residual nodal metastases detected on 131-I scans with SPECT/CT following initial surgery, but prior to 131-I therapy. Among the 146 patients with residual disease, there were a total of 218 distinct nodal metastases. Relative to the primary tumor, 71.6% (n=156) of metastases were ipsilateral, 22.0% (n=48) were contralateral, and 6.4% (n=14) were non-sided in the central neck (level VI/VII). Cervical lymph node levels VI, III, and II had the greatest frequencies of residual metastases (33.9%, 22.9%, 18.8%, respectively). Residual metastases occurred because of incomplete nodal dissection (49.3%), lack of preoperative identification (37.7%), or a combination of both (13%). Conclusion: Residual nodal metastasis following initial surgical treatment for regionally advanced differentiated thyroid cancer is rather common on highly sensitive 131-I scans with SPECT/CT and is due to both unrecognized nodal involvement preoperatively and incomplete removal of metastatic lymph nodes during compartment-orientated nodal dissection. The surgical management of high-risk DTC should include preoperative imaging to evaluate for nodal metastases in the central and lateral neck and compartment-orientated nodal dissection of involved compartments. Attention should be given to complete dissection in levels VI, III, and II, particularly when dissecting compartments ipsilateral to the primary tumor.

16 October 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
BRBenjamin S. Rosen
Benjamin S. Rosen
JWJoel R. Wilkie
Joel R. Wilkie
YSYilun Sun
Yilun Sun
MIMohannad Ibrahim
Mohannad Ibrahim
KCKeith A. Casper
Keith A. Casper
MMMichelle L. Mierzwa
Michelle L. Mierzwa

1 September 2020 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
LCLeila Chew
Leila Chew
BSBrooke M. Su-Velez
Brooke M. Su-Velez
JMJessa Elaine Miller
Jessa Elaine Miller
AWAlisha N. West
Alisha N. West

2 April 2019 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
LBLauren A. Bohm
Lauren A. Bohm
JMJessa Elaine Miller
Jessa Elaine Miller
NMNoëlle Morrell
Noëlle Morrell
JSJames D. Sidman
James D. Sidman
BRBrianne B. Roby
Brianne B. Roby